Celltrion said it will showcase its autoimmune disease treatment portfolio, including CT-P13 SC (brand name Remsima SC in Europe, Zymfentra in the U.S.), at the United European Gastroenterology Week (UEGW) in Berlin, Germany, from Oct. 4 to 7.

UEGW is Europe’s largest gastroenterology conference, drawing researchers and companies from around the world to share advances in inflammatory bowel disease (IBD), gastric cancer, and other digestive disorders.

Celltrion will host a solo exhibition booth at the main hall and conduct various scientific and promotional activities, including two “Meet the Expert” sessions. These will present real-world data comparing the intravenous (IV) and subcutaneous (SC) formulations of Remsima.

On the third day, the company will hold a symposium titled “When & for Whom: Intravenous vs Subcutaneous Therapies in IBD Maintenance,” exploring switching strategies from IV to SC therapy in IBD patients.

On the final day, Oct. 7, Celltrion will present post-hoc analysis results from its global phase 3 study of CT-P13 SC in moderate to severe ulcerative colitis and Crohn’s disease patients.

The study identified distinct baseline characteristics and clinical response patterns in patients who lost response compared with those who maintained response over two years, raising the possibility of predicting loss of response early in therapy.

The company expects the findings to further strengthen physician and patient confidence in CT-P13 SC, the only infliximab subcutaneous formulation developed and approved by Celltrion. The therapy has been gaining strong prescription growth in Europe and the U.S. thanks to its convenience and efficacy.

Celltrion will also highlight the rapid market growth of Yuflyma (ingredient: adalimumab), its high-concentration, citrate-free formulation of Humira. According to IQVIA, Yuflyma’s share in Europe rose to 24 percent in the first quarter of this year, narrowing the gap with the leading product to just one percentage point.

“Celltrion has consistently promoted the clinical value of CT-P13 SC at global congresses and received strong feedback from healthcare professionals,” a company official said. “We expect a positive reception at UEGW as well, and we will continue to expand our autoimmune portfolio to drive prescription growth and market share.”